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Abstract The prevalence of heart failure (HF) is increas-
ing. A distinction is made between diastolic HF (preserved
left ventricular ejection fraction (LVEF)) and systolic HF
(reduced LVEF). Advanced glycation end-products (AGEs)
are crystallized proteins that accumulate during ageing, but
are particularly increased in patients with diabetes mellitus
and in patients with renal failure. Through the formation
of collagen crosslinks, and by interaction with the
AGE-receptor, which impairs calcium handling and
increases fibrosis, AGE-accumulation has pathophysiolog-
ically been associated with the development of diastolic and
renal dysfunction. Interestingly, diastolic dysfunction is a
frequent finding in elderly patients, diabetic patients and in
patients with renal failure. Taken together, this suggests that
AGEs are related to the development and progression of
diastolic HF and renal failure. In this review, the role of
AGEs as a possible pathophysiological factor that link the
development and progression of heart and renal failure, is
discussed. Finally, the role of AGE intervention as a possible
treatment in HF patients will be discussed.
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Introduction
The prevalence of chronic heart failure (HF) increases fast
due to a population of increasing age and an increasing
prevalence of diabetes, resulting in a prevalence of HF of
10–20% in 70–80 year old people [1, 2]. Chronic HF may
occur in the presence of a preserved (diastolic HF) or
depressed (systolic HF) left ventricular ejection fraction
(LVEF), both having a similar (poor) prognosis [1, 3–5].
The prevalence of diabetes in systolic HF is estimated at
23% [6, 7] and in diastolic HF at 25–33% [8–11]. A pos-
sible mechanism underlying diastolic HF may be an
increase in advanced glycation end-products (AGEs).
AGEs are formed during a non-enzymatic reaction between
proteins and sugar residues [12, 13]. AGEs accumulate in
the body with age and are increased in patients with
chronic systolic and diastolic HF, diabetic complications
and renal dysfunction [12, 14]. In diabetic HF patients
tissue AGEs are more increased compared with HF patients
without diabetes [14]. Whether a difference in accumula-
tion of AGEs in diabetic patients between systolic and
diastolic HF is present, remains to be established. AGEs
can also activate the receptor for AGE (RAGE) and thereby
induce cardiovascular dysfunction [12]. In cardiovascular
disease, renal dysfunction often exists and is frequently
referred to as the cardiorenal syndrome [15]. The cardio-
renal syndrome is a disorder of the heart and kidneys
whereby acute or chronic dysfunction in one organ may
induce acute or chronic dysfunction in the other and vice
versa [16]. Interestingly, patients with renal dysfunction
often have diastolic dysfunction, and have an increased
prevalence of HF, in particular diastolic HF [17–20].
In addition, the risk factors for developing renal dysfunc-
tion have an overlap with the risk factors for the accumu-
lation of AGEs.
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Cardiorenal syndrome
In patients with chronic HF the co-existence of renal dys-
function is common, and renal failure is among the stron-
gest predictor of mortality in patients with HF [21]. This
co-existence has often been referred to as ‘‘cardiorenal
syndrome’’, in which acute or chronic dysfunction in one
organ may induce acute or chronic dysfunction in the other
organ [16, 22]. The pathophysiology of the cardiorenal
syndrome is multifactorial and involves decreased renal
perfusion, atherosclerosis and inflammation, endothelial
dysfunction and neurohormonal activation [23, 24].
Advanced glycation end-products
Advanced glycation end-products (AGEs) are a hetero-
geneous group of compounds, formed by oxidative and
non-oxidative reactions between proteins and sugar resi-
dues, called the Maillard reaction [12, 13]. The Maillard
reaction is a slow reaction and initiates when protein
amino groups are exposed to sugar adducts, and proceeds
from reversible Schiff base adducts to more stable, slowly
reversible Amadori products (e.g. HbA1c). It further
proceeds through the re-arrangement of Amadori products
to the formation of stable and irreversible AGE com-
pounds, for example Ne-(carboxymethyl)lysine (CML),
Ne-(carboxyethyl)lysine (CEL), and pentosidine [12, 13].
The final step is catalyzed by oxidative stress, defined as a
high steady state level of reactive oxygen species (ROS),
which causes an increase in AGEs [12]. This increase in
AGEs causes acceleration of oxidation, creating a vicious
circle. Rapid formation of AGEs occurs via another
pathway involving reactive carbonyl compounds (RCC)
during oxidative stress [25]. RCCs are produced from
lipids or carbohydrates reacting with ROS. AGE accu-
mulation in vivo occurs throughout the body, including
the skin, neural, vascular and renal tissue [26, 27].
Smoking cigarettes, heated, cooked or roasted food
products are possible sources of increased AGE accumu-
lation [12, 28, 29]. AGE degradation products are excre-
ted via the kidney [25].
AGE accumulation can be measured in blood and in
tissue. In blood, the preferred technique for determination
of CML and CEL is stable-isotope-dilution liquid chro-
matography tandem mass spectrometry (LC–MS/MS)
[30]. For determination of pentosidine in blood, a rapid
and sensitive high-performance liquid chromatography
(HPLC) method is considered the preferred technique
[31]. In skin tissue, AGE accumulation can be measured
at the volar side of the lower arm, more simple and non-
invasively with a skin auto-fluorescence (AF) reader
(AGE-reader) [32].
Advanced glycation end-products in diabetes mellitus
Accumulation of AGEs depends on both sugar concentra-
tion and the rate of protein turnover [33]. Diabetic patients
have a higher sugar concentration and therefore a higher
amount of AGEs compared to healthy controls. The rate of
formation of Amadori products is directly proportional to
the glucose concentration [33]. It has also been shown that
diabetes is a risk factor for the development of a more
impaired diastolic function, independent of age [34–36].
Furthermore, diabetes is not only increasing the risk of
developing HF, but also accelerates its occurrence [37].
This could be partly explained by a higher amount of
AGEs, which also occurs in HF patients [35]. Interestingly,
diabetics also have a more impaired diastolic function
compared with non-diabetics [34, 36]. We recently pro-
vided evidence for an association between tissue AGEs and
diastolic dysfunction (measured with mean E’), suggesting
that AGEs might explain diastolic dysfunction in diabetic
HF patients [14].
The RAGE axis
AGEs can also bind to the receptor of AGE (RAGE) and
thereby induce cardiovascular dysfunction [12]. RAGE is a
multi-ligand member of the immunoglobulin superfamily
of cell surface molecules that is expressed in a variety of
cell lines [38]. RAGE has a C-truncated secretory isoform,
soluble RAGE (sRAGE) that circulates in plasma [39].
sRAGE has been proposed to have an atherosclerotic-
protective function, in particular by acting as a decoy for
AGE [39–41]. AGE-accumulation can cause upregulation
of RAGE [42]. When AGE is interacting with RAGE,
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase is activated, causing activation and inflammation
of NF-kappaB, which induces further inflammation and can
increase AGE-accumulation, creating a vicious cycle [42].
Advanced glycation end-products in heart failure;
pathophysiology
Patients with diastolic HF have decreased ventricular
relaxation, abnormal active relaxation, and/or an increase in
ventricular and arterial stiffness [5, 43, 44]. The degree of
diastolic dysfunction is correlated with the severity of
myocardial fibrosis [45]. Several other mechanisms under-
lying diastolic HF have been proposed [12, 46–49]. One
possible mechanism could be an increase in AGEs. AGEs
may induce diastolic dysfunction in the heart through three
different pathways (Fig. 1). First, AGE accumulation causes
excessive cross-linking, which increases rigidity, thereby
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causing diastolic dysfunction as well as renal dysfunction.
Second, when AGEs interact with the AGE receptor, the
receptor is activated. Activation of AGE receptors (most
important receptor is Receptor for AGE (RAGE)) causes
increased fibrosis via the upregulation of transforming
growth factor-ß (TGF- ß). Third, when the AGE receptor is
exposed to AGEs, it causes a significant delay in calcium
reuptake. As a consequence, the duration of the repolarisa-
tion phase of the cardiac contraction may increase, subse-
quently causing diastolic dysfunction. Based on these data it
can be hypothesized that AGEs are a causal factor in dia-
stolic HF.
Advanced glycation end-products in heart failure;
evidence
Evidence for a role of AGEs in HF patients comes from
experimental work and increasing number of clinical
studies. In diabetic obese rats diastolic function measured
by cardiac catheterization has been shown to correlate with
levels of CML [50]. AGE receptor activation influences
calcium metabolism and thereby induces diastolic dys-
function. In transgenic mice that over expressed human
RAGE in the heart, diastolic and systolic intracellular
calcium concentration was reduced [51]. We recently
showed that tissue AGEs are related to diastolic function in
dialysis patients [18]. In another clinical study, we found
an association between tissue AGEs and diastolic function
(measured with mean E’) [14].
The overall prevalence of HF is increasing. Further-
more, roughly 50% of patients die in 4 years [1]. Several
factors have been established as independent predictors for
survival in HF patients, among which are LVEF, New York
Heart Association (NYHA) functional class, anemia and
renal function [46, 52–54]. Four studies investigated the
prognostic role of AGEs in HF patients. We have previ-
ously shown that plasma AGE CML was related to the
severity and prognosis of 102 HF patients, but after
correction for renal function this relation subsided [46].
In a second study in 141 HF patients, pentosidine was
related to severity of HF and it was an independent
risk factor to predict adverse clinical outcome [55].
However, the authors did not adjust their findings for all
known risk factors for mortality, such as hemoglobin and
gender. Furthermore, they may have introduced a possible
co-linearity problem by simultaneously introducing creat-
inine levels and estimated glomerular filtration rate (GFR)
in the multivariable model. A third study showed that pent-
osidine was an independent predictor for cardiac events in
160 HF patients [56]. Cardiac events were defined as a
composite end point of cardiac death and rehospitalization.
Advanced glycation end-products and renal failure;
pathophysiology
Several mechanisms underlying renal dysfunction have
been proposed, for example decreased renal perfusion,
atherosclerosis and inflammation, endothelial dysfunction
Fig. 1 Schematic representation of the pathophysiological pathways by which advanced glycation end-products causes diastolic heart failure
and renal dysfunction
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and neurohormonal activation [24, 57–59]. Another possible
mechanism could be an increase in AGEs. AGE-accumu-
lation in patients with renal dysfunction can occur through
two different pathways (Fig. 1). First, increased AGE
accumulation is caused by decreased clearance of AGE
degradation products. After modification or degradation in
proximal tubuli, AGEs are eventually cleared in the urine
[60–62]. Patients with renal dysfunction have a decreased
clearance and thereby accumulation of AGEs occurs. Sec-
ond, oxidative stress is enhanced in patients with renal
dysfunction, which also causes an increase in AGE forma-
tion [63]. An increase in AGEs causes acceleration of oxi-
dation, regenerating another increase in AGEs.
When endothelial cells in the kidney are stimulated by
AGEs, they release the pro-inflammatory mediators vas-
cular cell adhesion molecule-1 and intercellular adhesion
molecule-1 [61, 64, 65]. This may lead to tissue damage in
the kidney. In summary, it can be hypothesized that AGEs
are a possible mechanism underlying renal dysfunction.
Advanced glycation end-products and renal failure;
evidence
Evidence for a role of AGEs in patients with renal failure
comes from experimental and clinical studies. In 50 heal-
thy male Sprague-Dawley rats AGEs were increased by
adding AGE-modified albumin. This resulted in structural
changes in the glomerulus [66]. In healthy nondiabetic rats
and rabbits administrating AGE-modified albumin led to an
increase in vascular permeability and inflammation in the
vasculature [66]. In clinical studies, AGEs accumulate
during renal failure and dialysis [61, 67]. In patients with
renal failure plasma AGEs are elevated [67, 68]. In patients
on dialysis, tissue AGEs are even more increased compared
to patients with renal failure without dialysis [69]. After
renal transplantation AGE accumulation is lower than
during hemodialysis, but remains elevated [69].
Renal dysfunction is strongly associated with a poor
clinical outcome in HF patients [54, 70–72]. In addition,
AGEs are related to the severity of HF and its clinical
outcome as well. The prognostic role of AGEs in end-stage
renal disease has however been inconsistent [73–76]. Two
studies reported that high level of CML were associated
with an increased mortality, but a third study showed an
association with a decreased mortality. However, AGEs are
a heterogenous group of compounds. Several different
AGEs exist; some show cross-linking properties (pentosi-
dine), whereas others do not (CML and CEL). All three
studies only measured accumulation of the non-cross-
linking AGE CML. The cross-linking AGE pentosidine
was not measured. Furthermore CML was not measured
with LC–MS/MS, which is the preferred technique with
highest specificity. Another study reported that tissue AGE
was an independent predictor of mortality and associated
with cardiovascular disease in hemodialysis patients [77].
Further research is warranted to provide more insight
into the prognostic role of AGEs in patients with renal
dysfunction.
AGEs as a pathophysiological factor in cardiorenal
syndrome
The data presented in this review suggests that AGEs may
be involved as a pathophysiological factor in cardiorenal
syndrome (Fig. 1 and 2). AGE-accumulation is not
restricted to specific patient groups and accumulates in the
body with age. With ageing, diastolic function impairs,
while systolic function remains unchanged [1]. Diastolic
dysfunction can be caused by AGEs through increasing
rigidity and by causing a delay in calcium reuptake [12].
Patients with renal dysfunction are known to have increased
AGE-accumulation and diastolic dysfunction is a frequent
finding in these patients. The prevalence of diastolic dys-
function in dialysis patients varies from 25–87% depending
on definitions used and patients included [17, 20]. Diastolic
dysfunction predisposes to the development of HF, which
causes a further decrease in renal function, creating a
vicious circle (Fig. 1 and 2). [19]. Patients with diabetes
mellitus are also known to have increased AGE-accumu-
lation, independent of their age (Fig. 1). Accumulation of
AGEs depends on both sugar concentration and the rate of
protein turnover [33]. Furthermore, diabetic patients have a
more impaired diastolic function compared to non-diabetics
[34, 36]. Interestingly, the risk factors for developing renal
dysfunction have a certain overlap with the risk factors for
the accumulation of AGEs.
Taken together, diabetic patients and patients with renal
dysfunction have an increased accumulation of AGEs, and
an increased prevalence of diastolic dysfunction. In addi-
tion, patients with renal dysfunction and diabetes have
higher tissue AGE levels compared to patients with renal
dysfunction without diabetes [14, 25]. Whether this trans-
lates into a higher risk for new onset heart failure remains
to be established. Together with its pathophysiology, where
AGEs can be linked with diastolic dysfunction, we there-
fore suggest that increased amount of AGEs in heart and
renal failure can be a common pathophysiological factor
which causes both heart and renal failure (Fig. 2).
Interventions
AGE-accumulation was associated with a reduced survival
in patients with diabetes, renal failure, and HF and may
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therefore be a target for intervention. The adverse effects of
AGE-accumulation can be targeted in several ways.
In vitro and in vivo studies have shown that angiotensin II
type 1 receptor blockers (ARBs) can reduce AGE formation
[78–80]. ARBs prevent the production of reactive carbonyl
and dicarbonyl compounds (RCOs), which are critical pre-
cursors of AGEs [78–81]. However, we recently showed that
the angiotensin II type 1 receptor blocker eprosartan did not
decrease levels of AGEs, within 6 months, in patients with
hypertension and diastolic function [82].
AGE intake can also increase AGE-accumulation. Both
smoking and certain food products contain high levels of
AGEs and AGE precursors. Smoking cessation and low-
AGE diets have been shown to reduce AGE intake and
thereby AGE levels in blood [12, 28, 29].
Several AGE crosslink breakers, such as alagebrium and
TRC4186, are currently under investigation for use in dia-
betic and non-diabetic patients. We recently conducted the
BENEFICIAL study, the first prospective, randomized,
double-blind, placebo controlled study to examine the
effects of the AGE-breaker alagebrium on exercise capacity
and cardiac function in patients with systolic HF [83].
Conclusion
There is a pathophysiological and epidemiological link
between AGEs, renal dysfunction and heart failure. This
suggests that AGEs are related to the development and
progression of diastolic HF and renal failure. Therapies
targeted at reducing the effects of AGEs will have to
provide further evidence for this hypothesis.
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